They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]
Gilead Sciences (NASDAQ: GILD) has enjoyed remarkable success in the past year thanks to the launch of two instant billion-dollar blockbuster hepatitis C therapies, however, even best-in-breed biotech stocks like Gilead Sciences still face risks that could leave investors in the lurch. Read on to learn which three risks concern me most, and how they could impact Gilead Sciences down […]
Short interest has risen in a number of biotech names perceived as vulnerable to a selloff after a rally that has sent the Nasdaq Biotechnology Index <.NBI> up 42 percent over the last year even after this week’s declines.Overall, a screen of about 1,650 mid-cap U.S. companies shows biotech stocks, on average, have a short interest ratio of about 11.6 […]
Source: Flickr user stockmonkeys.com.Investing in clinical-stage biotech stocks isn’t for the faint of heart. The industry’s jaw-dropping pops and drops can be so dramatic as to suit these stocks only the most speculative portion of an investor’s portfolio.However, for investors willing to accept the risk of buying little-known biotech stocks such as Ophthotech , Portola Pharmaceuticals , and Insys Therapeutics […]
View photo.By and large, short interest among the leading biotechs and emerging pharmaceuticals reversed course and rose again between the January 30 and February 13 settlement dates.Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).Below we take a quick look at how these three stocks have fared recently and what […]
Small-cap biotechnology stocks offer some of the most breathtaking opportunities in the market, but some are better than others. For example, these three tiny biotech stocks are favorites among our Motley Fool experts, and that could mean they’re worth watching.Source: Portola Pharmaceuticals.: Warfarin’s decades long dominance as an anticoagulant used to treat heart disease and post-operative patients is waning, and […]
Source: Flickr user stockmonkeys.com .The pop-and-drop nature of the biotech industry makes owning stocks in the sector particularly dicey. But for investors willing to take on the risk of failure, a number of intriguing small-cap biotech companies are working on important new therapies that could make a big impact on patients’ lives and investors’ wallets. Here are three of thesecompanies.No. […]
11 ways to play biotech
The Fast Money traders discuss 11 ways to play biotech.
On a sluggish Monday for U.S. stocks, some biotechnology names shined. Celgene and Agios jumped nearly 3 percent while biotech-linked funds continued their steady climbs from last year.Acquisitions and breakthroughs abound in a sector brimming with options ripe for growth. Traders on CNBC’s “Fast Money” outlined their […]
Biotechnology’s mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them — but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there may be opportunities to discover emerging biotech companies with promising pipelines that could send their shares significantly higher in 2015. Ophthotech Corporation […]
Once again, deals and collaborations made news in the biotech sector with BioMarin (BMRN – Analyst Report) announcing its intention to acquire Prosensa (RNA – Snapshot Report) and Five Prime Therapeutics (FPRX – Snapshot Report) signing a second immuno-oncology focused deal with Bristol-Myers Squibb.Meanwhile, AbbVie (ABBV – Analyst Report) continues to progress with its hepatitis C virus (HCV) treatment with […]
